Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Mild traumatic brain injury (mTBI) is a major public health issue, representing 75-90% of all cases of TBI. In clinical settings, mTBI, which is defined as a Glascow Coma Scale (GCS) score of 13-15, can lead to various physical, cognitive, emotional, and psychological-related symptoms. To date, there are no pharmaceutical-based therapies to manage the development of the pathological deficits associated with mTBI. In this study, the neurotrophic and neuroprotective properties of glucose-dependent insulinotropic polypeptide (GIP), an incretin similar to glucagon-like peptide-1 (GLP-1), was investigated after its steady-state subcutaneous administration, focusing on behavior after mTBI in an in vivo animal model. The mTBI rat model was generated by a mild controlled cortical impact (mCCI) and used to evaluate the therapeutic potential of GIP. We used the Morris water maze and novel object recognition tests, which are tasks for spatial and recognition memory, respectively, to identify the putative therapeutic effects of GIP on cognitive function. Further, beam walking and the adhesive removal tests were used to evaluate locomotor activity and somatosensory functions in rats with and without GIP administration after mCCI lesion. Lastly, we used immunohistochemical (IHC) staining and Western blot analyses to evaluate the inflammatory markers, glial fibrillary acidic protein (GFAP), amyloid-β precursor protein (APP), and bone marrow tyrosine kinase gene in chromosome X (BMX) in animals with mTBI. GIP was well tolerated and ameliorated mTBI-induced memory impairments, poor balance, and sensorimotor deficits after initiation in the post-injury period. In addition, GIP mitigated mTBI-induced neuroinflammatory changes on GFAP, APP, and BMX protein levels. These findings suggest GIP has significant benefits in managing mTBI-related symptoms and represents a novel strategy for mTBI treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The impact of traumatic brain injuries: A global perspective
Hyder, A. A., Wunderlich, C. A., Puvanachandra, P., Gururaj, G., & Kobusingye, O. C. (2007) · Neurorehabilitation · doi:10.3233/nre-2007-22502 · Cited by 1,816 · cited 1×
“Traumatic brain injury (TBI) impacts 10 million persons annually and is not only a global health problem but also a serious socioeconomic burden.(1) Within the United States, TBI”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Microglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 1×
“and/or accelerated by systemic inflammation.(94) Indeed, after TBI, neuroinflammation occurs at acute and chronic stages after primary”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Axonal pathology in traumatic brain injury
Johnson, V. E., Stewart, W., & Smith, D. H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.013 · Cited by 1,273 · cited 1×
“elevated APP is considered a sensitive and specific marker of damaged axons and impaired synapses after TBI challenge,(14,26,40) and associates with injury severity and post-TBI outcome.(38,39)”
BackgroundAdult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention
Kumar, A., & Loane, D. J. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.008 · Cited by 710
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“reignited interest in the role of GIP and its targeting as a treatment strategy.(64)”
BackgroundEpidemiology of mild traumatic brain injury and neurodegenerative disease
Gardner, R. C., & Yaffe, K. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.03.001 · Cited by 673
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 3×
“The therapeutic effect of Ex-4 was mediated by GLP-1 receptor (GLP-1R) activation, because it can be blocked by the selective GLP-1R antagonist Exendin (9–39) and was ineffective in GLP-1R knockout mice.(60,61) GIP, like GLP-1, has a short half-life (approximately 7.”
BackgroundMethodSelf-citation
Cited by
Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 258
Self-citationSalameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“Promoting neuroprotection in many, not necessarily mutually exclusive, ways, specifically by enhancing DNA repair [151]; increasing expression and signaling of brain-derived neurotrophic factor (BDNF) [55, 152, 153]; reducing Aβ oligomers [38], Aβ plaque load [38-40, 154-157], Aβ toxicity [158-162], advanced glycation…”
BackgroundProtective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Salles, G. N., Calió, M. L., Hölscher, C., Pacheco-Soares, C., Porcionatto, M., & Lobo, A. O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107813 · Cited by 71
Metadata
- Authors
- Yu, Y.-W., Hsieh, T.-H., Chen, K.-Y., Wu, J. C.-C., Hoffer, B. J., Greig, N. H., Li, Y., Lai, J.-H., Chang, C.-F., Lin, J.-W., Chen, Y.-H., Yang, L.-Y., & Chiang, Y.-H.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2016-11-15
- Volume
- 33
- Issue
- 22
- Pages
- 2044-2054
- ISSN
- 0897-7151 (ISSN-L)
- 1557-9042
- OpenAlex
- W2370951863
- Cited by
- 39
- References
- 16
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats. https://app.cochat.ai/papers/10.1089/neu.2015.4229
- The paper
- Yu, Y.-W., Hsieh, T.-H., Chen, K.-Y., Wu, J. C.-C., Hoffer, B. J., Greig, N. H., Li, Y., Lai, J.-H., Chang, C.-F., Lin, J.-W., Chen, Y.-H., Yang, L.-Y., & Chiang, Y.-H. (2016). Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats. Journal of Neurotrauma. https://doi.org/10.1089/neu.2015.4229
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.